IMJUDO
PeakmAbBLAINTRAVENOUSINJECTABLE
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMJUDO (tremelimumab-actl) is a monoclonal antibody that blocks CTLA-4, a negative regulator of T-cell immunity, to treat patients with ALK-positive anaplastic lymphoma kinase genomic tumor aberrations. By releasing CTLA-4-mediated inhibition, it enhances T-cell proliferation and anti-tumor activity. This immunotherapy represents a checkpoint inhibitor approach in oncology.
$0.002BPart D
PeakEarly commercial phase with moderate Part D uptake (65 claims in 2023) suggests ongoing market penetration efforts and growing team investment in medical affairs and field infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Imjudo & Imfinzi PMS
Started Apr 2025
246 enrolled
Hepatocellular Carcinoma
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
Started Jun 2023
296 enrolled
Carcinoma, Non-Small-Cell Lung
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Started May 2023
1,200 enrolled
Unresectable Hepatocellular Carcinoma
Career Relevance
IMJUDO represents a growth-stage opportunity with 86 linked jobs across R&D, Medical Affairs, Clinical Operations, and Regulatory Affairs, indicating active team building at AstraZeneca. Roles span from molecular science specialists to medical leadership, reflecting both clinical development and commercial launch infrastructure.
Worked on IMJUDO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.